CorMedix (CRMD) Convertible Debt (2012 - 2019)

CorMedix's (CRMD) quarterly Convertible Debt came in at $6.7 million in Q2 2019, up 4.77% quarter-over-quarter from $6.4 million in Q1 2019.

CorMedix (CRMD) Convertible Debt (2012 - 2019) Analysis & Trends

CorMedix has disclosed Convertible Debt across 4 years of filings, most recently posting $6.7 million for Q2 2019.

Convertible Debt for Q2 2019 came in at $6.7 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2019 was $6.7 million (changed N/A YoY), and the FY2018 annual result was $6.1 million, changed N/A from the prior year.
Convertible Debt came in at $6.7 million for Q2 2019 at CorMedix, up from $6.4 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $6.7 million in Q2 2019 to a low of $6.1 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	CorMedix	631,378.03	-154.57 Mn	107.31 Mn

Download Data